Walking capacities in multiple sclerosis measured by global positioning system odometer
- PMID: 17439888
- DOI: 10.1177/1352458506070667
Walking capacities in multiple sclerosis measured by global positioning system odometer
Abstract
We used a global positioning satellite technology odometer to determine the maximum objective walking distance capacity (MOWD) of patients with multiple sclerosis (MS). The MOWD correlated with Expanded Disability Status Scale (EDSS) score (r(2) =0.41; P <0.0001), the MSWS-12 scale (r(2) =0.46; P <0.0001), time to walk 10 m (r(2) =0.51; P <0.02) and walking speed (r(2) =0.75; P <0.001). Limitation of walking capacities was measurable up to 4550 m, strikingly above the 500-m limit of the EDSS. This objective odometer is a promising tool for evaluation and follow-up of patients with MS.
Similar articles
-
Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls.Mult Scler. 2008 Apr;14(3):383-90. doi: 10.1177/1352458507082607. Epub 2007 Oct 17. Mult Scler. 2008. PMID: 17942508 Clinical Trial.
-
Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis.Neurorehabil Neural Repair. 2011 Sep;25(7):672-9. doi: 10.1177/1545968310397204. Epub 2011 Mar 24. Neurorehabil Neural Repair. 2011. PMID: 21436388
-
Relapses and progression of disability in multiple sclerosis.N Engl J Med. 2000 Nov 16;343(20):1430-8. doi: 10.1056/NEJM200011163432001. N Engl J Med. 2000. PMID: 11078767
-
The transition from relapsing-remitting MS to irreversible disability: clinical evaluation.Neurol Sci. 2003 Dec;24 Suppl 5:S268-70. doi: 10.1007/s10072-003-0171-6. Neurol Sci. 2003. PMID: 14652786 Review.
-
Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis.Expert Rev Pharmacoecon Outcomes Res. 2010 Oct;10(5):595-603. doi: 10.1586/erp.10.60. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20950074 Review.
Cited by
-
The inter- and intra-unit variability of a low-cost GPS data logger/receiver to study human outdoor walking in view of health and clinical studies.PLoS One. 2012;7(2):e31338. doi: 10.1371/journal.pone.0031338. Epub 2012 Feb 20. PLoS One. 2012. PMID: 22363623 Free PMC article. Clinical Trial.
-
Measuring Outdoor Walking Capacities Using Global Positioning System in People with Multiple Sclerosis: Clinical and Methodological Insights from an Exploratory Study.Sensors (Basel). 2021 May 4;21(9):3189. doi: 10.3390/s21093189. Sensors (Basel). 2021. PMID: 34064381 Free PMC article.
-
[4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].Nervenarzt. 2010 Feb;81(2):203-11. doi: 10.1007/s00115-009-2902-2. Nervenarzt. 2010. PMID: 20112006 Review. German.
-
The accuracy of a simple, low-cost GPS data logger/receiver to study outdoor human walking in view of health and clinical studies.PLoS One. 2011;6(9):e23027. doi: 10.1371/journal.pone.0023027. Epub 2011 Sep 13. PLoS One. 2011. PMID: 21931593 Free PMC article.
-
Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.Drugs R D. 2013 Sep;13(3):175-81. doi: 10.1007/s40268-013-0020-x. Drugs R D. 2013. PMID: 23873597 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources